<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00741455</url>
  </required_header>
  <id_info>
    <org_study_id>D0345</org_study_id>
    <nct_id>NCT00741455</nct_id>
  </id_info>
  <brief_title>Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies</brief_title>
  <official_title>Non-Myeloablative Chemotherapy Followed by HLA-Matched Related Allogeneic Stem Cell Transplantation for Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine disease-free survival, overall survival, time to&#xD;
      progression, regimen-related toxicity and/or treatment-related mortality in patients with&#xD;
      hematologic malignancies treated with non-myeloablative chemotherapy followed by allogeneic&#xD;
      stem cell transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogeneic bone marrow transplantation (BMT) became feasible in the 1960s after elucidation&#xD;
      of the Human Leukocyte Antigen (HLA) complex. Since then, the therapy has evolved into an&#xD;
      effective treatment for many hematologic disorders. Otherwise incurable malignancies are&#xD;
      frequently cured by this approach, with the likelihood of cure ranging from 10% to 85%,&#xD;
      depending on the disease and the disease status. The treatment strategy incorporates very&#xD;
      large doses of chemotherapy and often radiation to eliminate cancer cells and to&#xD;
      immunosuppress the recipient to allow the engraftment of donor cells. Donor cells give rise&#xD;
      to hematopoiesis within two to three weeks, rescuing the patient from the effects of high&#xD;
      dose therapy. In the ideal situation, immune recovery and recipient-specific tolerance occurs&#xD;
      over the following 6-18 months, and the patient is cured of their underlying malignancy, off&#xD;
      immunosuppression, with a functionally intact donor-derived immune system. However,&#xD;
      complications are common and include fatal organ damage from the effects of high dose&#xD;
      chemotherapy, infection, hemorrhage, and, in particular, graft-versus-host disease (GvHD). A&#xD;
      realistic estimate of transplant-related mortality in the standard HLA-matched sibling&#xD;
      setting is approximately 25%. The risk of treatment-related mortality limits the success and&#xD;
      certainly precludes its use in older patients. Thus, new strategies in transplantation are&#xD;
      needed.&#xD;
&#xD;
      With the growing understanding that much of the curative potential of allogeneic bone marrow&#xD;
      or stem cell transplant (SCT) is from an immune anti-tumor effect of donor cells, known as&#xD;
      graft-versus-leukemia (GvL) or graft-versus-tumor (GvT), a new strategy is being employed&#xD;
      that shifts the emphasis from high-dose chemo-radiotherapy to donor-derived, immune-mediated&#xD;
      anti-tumor therapy. In this approach, patients receive preparative regimens that, while&#xD;
      having some anti-tumor activity, are mainly designed to be immunosuppressive enough to allow&#xD;
      engraftment of donor stem cells and lymphocytes. Engrafted lymphocytes then mediate a GvL&#xD;
      effect; if the GvL effect of the initial transplant is not sufficient, then additional&#xD;
      lymphocytes may be infused (achievement of engraftment allows additional lymphocytes to&#xD;
      &quot;take&quot; in the recipient without requiring any additional conditioning of the recipient). The&#xD;
      lower intensity of the preparative regimen lessens the overall toxicity by minimizing the&#xD;
      doses of chemo-radiotherapy. In addition, less intensive preparative regimens may be&#xD;
      associated with less GvHD, as much evidence suggests that high-dose therapy contributes to&#xD;
      the syndrome of GvHD by causing tissue damage, leading to a cytokine milieu which enhances&#xD;
      activation of graft-versus-host (GvH) effector cells. Thus, such an approach may allow the&#xD;
      safer use of allogeneic transplants in standard populations and may allow extension of&#xD;
      allogeneic transplantation to patients who could not receive standard (myeloablative)&#xD;
      transplants because of age or co-morbidities. This protocol investigates a non-myeloablative&#xD;
      transplant approach, using fludarabine and cyclophosphamide, to allow engraftment of&#xD;
      allogeneic cells, which may then mediate anti-tumor effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Successful Bone Marrow Engraftment</measure>
    <time_frame>Within 30 days of bone marrow transplant</time_frame>
    <description>Rates of successful engraftment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieve Complete Donor Chimerism</measure>
    <time_frame>Post-transplant days +30, +60, +100, +180 and +365</time_frame>
    <description>Complete donor chimerism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Graft-Versus-Host-Disease</measure>
    <time_frame>Post-transplant procedure through death</time_frame>
    <description>Collect the number of incidents of acute and chronic graft-versus-host disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Measured in Participants</measure>
    <time_frame>Up to 15 Years Post-Transplant</time_frame>
    <description>Mortality rates in subjects after successful completion of a bone marrow transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection of Adverse Events</measure>
    <time_frame>Until the 6th Bone Marrow Transplant performed in subjects on study</time_frame>
    <description>Determine the level of toxicity experienced by subjects who receive protocol treatment and bone marrow transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Disease Response</measure>
    <time_frame>Post-transplant procedure through death</time_frame>
    <description>Review and assess the tumor response rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Study Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be &gt; 5 x 106 CD34+cells/kg of recipient.&#xD;
Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.&#xD;
Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml.</description>
    <arm_group_label>Study Treatment</arm_group_label>
    <other_name>HLA-Matched Related Allogeneic Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>10 mcg/kg/day on days 5, 6, and 7</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>25 mg/m2/d IV over 30 minutes on days -6 to -2</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>1 g/m2/d IV on days -3 and -2</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-75 years&#xD;
&#xD;
          -  Diseases&#xD;
&#xD;
               1. Chronic myelogenous leukemia (CML)&#xD;
&#xD;
                    -  First chronic phase or later&#xD;
&#xD;
                    -  Accelerated phase&#xD;
&#xD;
               2. Acute myelogenous or lymphoblastic leukemia (AML or ALL)&#xD;
&#xD;
                    -  Second or subsequent remission&#xD;
&#xD;
                    -  Patients who have failed an autologous PBSC transplant&#xD;
&#xD;
                    -  First remission with poor risk features, including, but not limited to: For&#xD;
                       AML- complex chromosome karyotype, abnormalities of chromosome 5 or 7, 12p-,&#xD;
                       13+, 8+, t(9;22), t(11;23) For ALL- t(9;22), t(4;11), t(1;19), myeloid&#xD;
                       antigen coexpression&#xD;
&#xD;
               3. Myelodysplastic syndrome (MDS)&#xD;
&#xD;
               4. Multiple myeloma - high risk myeloma (poor responders, relapse after autologous&#xD;
                  PBSCT, chromosome 13 abnormalities)&#xD;
&#xD;
               5. Hodgkin's disease&#xD;
&#xD;
                    -  Primary refractory disease&#xD;
&#xD;
                    -  Relapsed disease (first relapse or later)&#xD;
&#xD;
                    -  Patients who have failed an autologous PBSC transplant&#xD;
&#xD;
               6. Non-Hodgkin's lymphoma Low grade (by Working Formulation)&#xD;
&#xD;
                    -  Relapsed, progressive disease after initial chemotherapy&#xD;
&#xD;
                    -  Primary refractory disease or failure to respond (&gt;PR) to initial&#xD;
                       chemotherapy&#xD;
&#xD;
                    -  Patients who have failed an autologous PBSC transplant Intermediate grade&#xD;
                       (by Working Formulation)&#xD;
&#xD;
                    -  Relapsed disease&#xD;
&#xD;
                    -  Primary refractory disease or failure to respond (&gt;PR) to initial chemo&#xD;
&#xD;
                    -  Mantle cell lymphoma&#xD;
&#xD;
                    -  Patients who have failed an autologous PBSC transplant&#xD;
&#xD;
               7. Chronic lymphocytic leukemia (CLL)&#xD;
&#xD;
                    -  Patients newly diagnosed with poor prognostic factors, including CD38&#xD;
                       expression, Chromosome 11 or 17 abn&#xD;
&#xD;
                    -  T-CLL/PLL&#xD;
&#xD;
                    -  Relapsed or progressive disease, or refractory after Fludarabine&#xD;
&#xD;
                    -  Patients who have failed an autologous PBSC transplant&#xD;
&#xD;
          -  Donor Availability: Six of six matched HLA A, B and DR identical sibling (or parent or&#xD;
             child) or 5/6 related donor with single mismatch at Class I antigen (A or B)&#xD;
&#xD;
          -  Karnofsky performance status of &gt;70%&#xD;
&#xD;
          -  Serum bilirubin &lt;2x upper limit of normal; transaminases &lt;3x normal (unless due to&#xD;
             disease)&#xD;
&#xD;
          -  24 hr urine creatinine clearance of &gt;40 ml/min.&#xD;
&#xD;
          -  DLCO &gt;50% predicted&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt;35%&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  Non-pregnant female&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  No major organ dysfunction or psychological problems that preclude compliance and&#xD;
             completion of the clinical trial.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Major organ dysfunction&#xD;
&#xD;
          -  Pregnant or lactating female&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Psychological problems that preclude compliance and completion of the clinical trial&#xD;
&#xD;
          -  Any other condition, that in the judgement of the investigator, affects participant&#xD;
             safety or overall participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John M Hill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth R Meehan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 25, 2008</study_first_submitted>
  <study_first_submitted_qc>August 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2008</study_first_posted>
  <results_first_submitted>May 15, 2020</results_first_submitted>
  <results_first_submitted_qc>October 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 23, 2020</results_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>John M. Hill, Jr., MD</investigator_full_name>
    <investigator_title>Director, Allogeneic Bone Marrow Transplant Program</investigator_title>
  </responsible_party>
  <keyword>Non-myeloablative transplant</keyword>
  <keyword>Chronic Myelogenous Leukemia</keyword>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Hodgkin's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 18, 2010</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT00741455/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Treatment</title>
          <description>Chemo, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate&#xD;
Stem Cell Transplant: Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be &gt; 5 x 106 CD34+cells/kg of recipient.&#xD;
Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.&#xD;
Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml.&#xD;
G-CSF: 10 mcg/k</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Treatment</title>
          <description>Chemo, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate&#xD;
Stem Cell Transplant: Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be &gt; 5 x 106 CD34+cells/kg of recipient.&#xD;
Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.&#xD;
Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml.&#xD;
G-CSF: 10 mcg/k</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="38" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Successful Bone Marrow Engraftment</title>
        <description>Rates of successful engraftment.</description>
        <time_frame>Within 30 days of bone marrow transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Treatment</title>
            <description>Chemo, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate&#xD;
Stem Cell Transplant: Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be &gt; 5 x 106 CD34+cells/kg of recipient.&#xD;
Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.&#xD;
Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml.&#xD;
G-CSF: 10 mcg/k</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Successful Bone Marrow Engraftment</title>
          <description>Rates of successful engraftment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Engrafted &lt;/= 15 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Engrafted 16-30 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Engrafted &gt;30 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieve Complete Donor Chimerism</title>
        <description>Complete donor chimerism</description>
        <time_frame>Post-transplant days +30, +60, +100, +180 and +365</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Treatment</title>
            <description>Chemo, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate&#xD;
Stem Cell Transplant: Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be &gt; 5 x 106 CD34+cells/kg of recipient.&#xD;
Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.&#xD;
Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml.&#xD;
G-CSF: 10 mcg/k</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieve Complete Donor Chimerism</title>
          <description>Complete donor chimerism</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Chimerism 30 Days Post Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Chimerism 60 Days Post Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Chimerism 100 Days Post Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Chimerism 180 Days Post Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Chimerism 365 Days Post Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chimerism Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not achieve complete donor chimerism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Graft-Versus-Host-Disease</title>
        <description>Collect the number of incidents of acute and chronic graft-versus-host disease</description>
        <time_frame>Post-transplant procedure through death</time_frame>
        <population>Data was not collected for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Study Treatment</title>
            <description>Chemo, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate&#xD;
Stem Cell Transplant: Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be &gt; 5 x 106 CD34+cells/kg of recipient.&#xD;
Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.&#xD;
Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml.&#xD;
G-CSF: 10 mcg/k</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Graft-Versus-Host-Disease</title>
          <description>Collect the number of incidents of acute and chronic graft-versus-host disease</description>
          <population>Data was not collected for this outcome measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Measured in Participants</title>
        <description>Mortality rates in subjects after successful completion of a bone marrow transplant</description>
        <time_frame>Up to 15 Years Post-Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Treatment</title>
            <description>Chemo, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate&#xD;
Stem Cell Transplant: Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be &gt; 5 x 106 CD34+cells/kg of recipient.&#xD;
Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.&#xD;
Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml.&#xD;
G-CSF: 10 mcg/k</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Measured in Participants</title>
          <description>Mortality rates in subjects after successful completion of a bone marrow transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Survival &lt; 1 year post-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survival 1 to &lt; 5 years post-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survival 5 to &lt; 10 years post-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survival 10+ years post-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Collection of Adverse Events</title>
        <description>Determine the level of toxicity experienced by subjects who receive protocol treatment and bone marrow transplant</description>
        <time_frame>Until the 6th Bone Marrow Transplant performed in subjects on study</time_frame>
        <population>Data was not collected for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Study Treatment</title>
            <description>Chemo, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate&#xD;
Stem Cell Transplant: Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be &gt; 5 x 106 CD34+cells/kg of recipient.&#xD;
Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.&#xD;
Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml.&#xD;
G-CSF: 10 mcg/k</description>
          </group>
        </group_list>
        <measure>
          <title>Collection of Adverse Events</title>
          <description>Determine the level of toxicity experienced by subjects who receive protocol treatment and bone marrow transplant</description>
          <population>Data was not collected for this outcome measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess Disease Response</title>
        <description>Review and assess the tumor response rate</description>
        <time_frame>Post-transplant procedure through death</time_frame>
        <population>Data was not collected for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Study Treatment</title>
            <description>Chemo, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate&#xD;
Stem Cell Transplant: Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be &gt; 5 x 106 CD34+cells/kg of recipient.&#xD;
Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.&#xD;
Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml.&#xD;
G-CSF: 10 mcg/k</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Disease Response</title>
          <description>Review and assess the tumor response rate</description>
          <population>Data was not collected for this outcome measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-Cause Mortality was assessed for up to 15 years post-transplant. Adverse event data was not collected.</time_frame>
      <desc>Serious Adverse Event data was not collected. Other [Not Including Serious] Adverse Events were not monitored/assessed</desc>
      <group_list>
        <group group_id="E1">
          <title>Study Treatment</title>
          <description>Chemo, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate&#xD;
Stem Cell Transplant: Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be &gt; 5 x 106 CD34+cells/kg of recipient.&#xD;
Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.&#xD;
Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml.&#xD;
G-CSF: 10 mcg/k</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Darcie Findley</name_or_title>
      <organization>Dartmouth-Hitchcock Medical Center</organization>
      <phone>603-650-4595</phone>
      <email>darcie.l.findley@hitchcock.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

